Targeting vascular endothelial growth factor in renal cell carcinoma.
Renal cancer is the most lethal of all urological malignancies with overall 5-year survival rates of around 60%. The predominant reason for the poor prognosis of this cancer has been the relative lack of effective systemic therapy for advanced metastatic disease. Until recently immunotherapy with in...
Main Authors: | Patel, N, Muneer, A, Blick, C, Arya, M, Harris, A |
---|---|
Format: | Journal article |
Jezik: | English |
Izdano: |
2009
|
Podobne knjige/članki
-
Vascular endothelial growth factor expression in renal cell carcinoma
od: Mohtarrudin, Norhafizah, et al.
Izdano: (2018) -
Renal damage associated with anti-vascular endothelial growth factor treatment
od: Pradeep K Panigrahi, et al.
Izdano: (2024-01-01) -
Sirolimus Toxicity and Vascular Endothelial Growth Factor Release From Islet and Renal Cell Lines
od: Laugharne, M, et al.
Izdano: (2007) -
Cabozantinib and Axitinib After Vascular Endothelial Growth Factor Therapy in Patients with Advanced Renal Cell Carcinoma: A Retrospective Cohort Study from England
od: Brown, J, et al.
Izdano: (2024) -
Vascular endothelial growth factor expression in lung cancer.
od: O'Byrne, K, et al.
Izdano: (1998)